May 31, 2018 - This company hopes to profit from shaking up how doctors treat lower back pain.
May 30, 2018 - AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline
May 30, 2018 - Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.
May 30, 2018 - Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.
May 28, 2018 - AstraZeneca Plc. (AZN) announces positive overall survival (OS) data from an interim analysis of a phase III PACIFIC study evaluating its oncology candidate, Imfinzi.
May 25, 2018 - Names on the move ahead of the open.
May 22, 2018 - Optimism is growing that this cancer drug developer will be the next biotech to be acquired.
May 22, 2018 - Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.
May 21, 2018 - AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
May 18, 2018 - AstraZeneca PLC (NYSE:AZN) Q1 2018 Results Earnings Conference Call May 18, 2018 07:00 AM ET Executives Pascal Soriot - CEO Dave Fredrickson - EVP, Oncology Business Unit Mark Mallon - EVP, GPPS, GMA